A trial of the coronavirus vaccine tipped to be the front runner in the fight against Covid-19 has been put on hold after a UK volunteer suffered a suspected serious adverse reaction.
AstraZeneca Plc - which is working alongside the University of Oxford - has confirmed it had had to pause development of the vaccine "to allow review of safety data".
While the pause raises serious safety concerns, Health Secretary Matt Hancock claims that it's 'not necessarily a setback.' Speaking this morning, Mr Hancock said that AstraZeneca's decision to pause its vaccine trial was a challenge but would not necessarily set back efforts to develop a vaccine. "It is obviously a challenge to this particular vaccine trial," Hancock said on Sky News when